• About
  • Careers
  • Raynews
  • ESG
  • Contact us
  • Distributor Portal
  • Home
  • Devices
    • IOLs
      • Overview
      • RayOne Family
      • Galaxy
      • RayOne EMV
      • Monofocal
      • Trifocal
      • Toric
      • Supplementary
      • RayOne Injector
      • Duet Procedure
    • Sophi
      • Overview
    • HASA Optix
      • Overview
  • Drugs
    • OVDs
      • Overview
    • Eye care
      • Overview
      • AEON Sodium Chloride
      • Dropodex
      • Catacrom
    • Artificial tears
      • Overview
      • AEON Family
      • Hydromoor
      • Ilube
    • Omidria
      • Overview
  • Digital
    • RayPro
      • Overview
    • Raytrace
      • Overview

Home > You searched for AEON

Search results for AEON

Total results found = 19

AEON

In the NEAR tab you will find different levels of trainings on Rayner products. This section also includes basic training on the structure of the eye, the cataract surgery process, and basic aspects of ophthalmic optics & ophthalmic drugs.


Enhance Your Dry Eye Treatment Options with AEON Tear Film Therapies by Ms Thomson

AEON, Dry Eye, Eye drops, Cross Linked, Sodium Hyaluronate, Vitamin, Phosphate, Preservative, Protect


AEON eye drops now available in Boots Opticians across the UK

May 19, 2022 – Worthing-based Rayner, a global innovator in cataract and refractive surgery solutions and the only UK manufacturer of intraocular lenses (IOLs), announced today that AEON, its surgery-focused premium eye drops are now available in one of the leading UK optician chains, Boots Opticians, with more than 500 branches across the UK. In the UK,


AEON REPAIR


AEON PROTECT


AEON Sodium Chloride


AEON PROTECT PLUS


AEON Family

Your complete eye drop family, designed for before and after eye surgery. Recently published research suggests that dry eye may be a hidden obstacle to some patients’ satisfaction with their cataract surgery. That’s why we created AEON, a new eye drop family which aims to help patients manage their condition and improve their post-surgical outcomes.


Rayner continues European growth with direct presence in France

Worthing, United Kingdom. Leading ophthalmology company Rayner has today announced its direct entry into the French cataract and refractive market. Based out of Lille in the Hauts-de-France region, Rayner has a growing team of experienced Ophthalmic Specialist Area Managers, focused on delivering the highest levels of service and support. Through this team, French ophthalmologists now


National Key Account Manager – Ocular Surface Disease

The key objective of the National Account Manager – OSD is to achieve AEON product listings and sales within Pharmacies, Pharmacy Retail Groups and Optical Retail Chains and to create awareness for the therapy and our portfolio amongst prescribing physicians in Germany and the DACH region. Managing and developing key accounts across the Germany you will need to be an accomplished strategic account manager experienced working with Pharmacies, Pharmacy Retail Groups and Pharmacy Wholesalers. Your territory will be Germany, but business development in Austria and Switzerland may be a developing task. You should anticipate extensive travel and will ideally be located in Central Germany. Rayner is a leading developer and manufacturer of ophthalmic implants and pharmaceuticals; it specialises in intraocular lenses (IOLs) and related products used in cataract and refractive surgery. Since the development of the first IOL, Rayner has continuously pioneered IOL design with a goal to improve vision and restore sight worldwide. Today, Rayner’s mission remains to deliver innovative and clinically superior ophthalmic solutions that respond to the expectations of our global customers to improve sight and quality of life for their patients.


Eye health Q&A with Dr Allon Barsam

AEON and Sulcoflex Trifocal Clinical Article Barsam A


Rayner Partners with Wolffsohn Research

FEBRUARY 22 2022 – Worthing, United Kingdom. Rayner, a global innovator in cataract and refractive surgery, announced today that it has agreed a development partnership with Wolffsohn Research Ltd to accelerate the development of its Digital Health platform. Rayner launched RayPRO, a digital platform to collect patient reported outcomes (PRO), in 2019 and has since collected data


Ilube

Your complete eye drop family, designed for before and after eye surgery. Recently published research suggests that dry eye may be a hidden obstacle to some patients’ satisfaction with their cataract surgery. That’s why we created AEON, a new eye drop family which aims to help patients manage their condition and improve their post-surgical outcomes.


Hydromoor

Your complete eye drop family, designed for before and after eye surgery. Recently published research suggests that dry eye may be a hidden obstacle to some patients’ satisfaction with their cataract surgery. That’s why we created AEON, a new eye drop family which aims to help patients manage their condition and improve their post-surgical outcomes.


Website Terms of Use

PLEASE READ THESE TERMS AND CONDITIONS CAREFULLY BEFORE USING THIS SITE This website www.rayner.com (“the Site”) is produced and operated by Rayner Intraocular Lenses Limited (“Rayner”). These Terms of Use contain important information and set out your rights and responsibilities as a user of this website. 1. Purpose and Effect These Terms of Use are legally binding


Eye health Q&A with Dr Allon Barsam. Restoring your vision with cataract surgery_Sulcoflex Trifocal

AEON|cataract surgery|dry eye disease|Sulcoflex Trifocal|Tear film Clinical Article Barsam A


Diagnosing and Treating Ocular Surface Disease in Surgical Patients

AEON|Beni­tez-del-Castillo|Cochener-Lamard|cross-linking|drops|dry eye|dry eye disease|dry eye drops|Guell|Hjortdal|hyaluronic acid|Koppen|ocular surface|ocular surface disease Clinical Article Guell J, Cochener-Lamard B, Koppen C, Benitez-del-Castillo JM, Hjortdal J


Efficacy of eyedrops containing cross-linked hyaluronic acid and coenzyme Q10 in treating patients with mild to moderate dry eye

AEON|Alibrandi|Aragona|Calapai|cross-linking|drops|dry eye|dry eye disease|dry eye drops|hyaluronic acid|Mannucci|ocular surface|Postorino|Puzzolo|Rania Peer Review Publication Postorino E, Rania L, Aragona E, Mannucci C, Alibrandi A, Calapai G, Puzzolo D, Aragona P


A Crosslinked HA-Based Hydrogel Ameliorates Dry Eye Symptoms in Dogs

AEON|cross-linking|drops|dry eye|dry eye disease|dry eye drops|hyaluronic acid|Mann|ocular surface|Williams Peer Review Publication Williams DL, Mann BK


Important Notice

  • Global Presence
  • Company Profile
  • Management Team
  • Careers
  • History
  • Research & Development

Legal & Compliance

  • Rayner Group Quality Management System
  • Vigilance Surveillance
  • Website Terms of Use
  • Use of Cookies
  • Privacy Policy
  • Terms and Conditions of Sale
  • Terms and Conditions of Purchase
  • Returns Policy

Corporate Social Responsibility

  • Compliance
  • Modern Slavery Statement
  • Gender Pay Gap Report
  • ESG Commitment Statement
  • Community Responsibility
  • Codes of Conduct
  • Whistleblowing Policy
  • RSG Carbon Reduction Plan

Contact us

Global HQ & UK Office:

Rayner
The Ridley Innovation Centre
10 Dominion Way
Worthing
West Sussex
BN14 8AQ
United Kingdom
Registered in England: 615539

  • About
  • Careers
  • Raynews
  • ESG
  • Contact us
  • Distributor Portal

© 2026 Rayner Group

  • Twitter
  • linkedin
  • youtube
  • Rayner Eyetube EyeTube
  • Instagram

Sign up to receive carefully selected news and information from Rayner.

Rayner is a British medical device manufacturer.

  • By clicking 'Subscribe' you consent to receiving carefully selected news and information from Rayner by email. You can unsubscribe at any time by following the link at the bottom of every email. Privacy policy

  • This field is for validation purposes and should be left unchanged.

Make an Enquiry

If you have a product complaint or experience a problem with a Rayner product, please immediately contact feedback@rayner.com
This field is for validation purposes and should be left unchanged.